Skip to content
November 18, 2024

MPM BioImpact-Founded Company, Syndax, Announces FDA Approval of Revuforj® (revumenib)

You are about to leave MPM BioImpact's website. MPM BioImpact is not responsible for the content on other companies' websites.

Cancel Continue